Radiology

Bracco and the European Society of Radiology build on long-standing partnership at ECR 2025 through new campaign to advance innovative and sustainable approaches in radiology

Bracco will present an immersive experience at its booth to educate congress attendees on the importance of corporate commitment to sustainability and how its MR imaging portfolio contributes to the progress of sustainable radiology. Bracco will reinforce its commitment to deepening…

RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP™ Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath, an innovative, FDA-cleared device, highlighted its recent abstract presentation at the 2025 Society of Interventional Oncology Annual Conference (“SIO 2025”) in Las Vegas, Nevada. The abstract published promising […]

Positron Corporation Announces Sale of Attrius PET and NeuSight PET-CT Scanners

Niagara Falls, NY, Jan. 28, 2025 (GLOBE NEWSWIRE) — Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leading molecular imaging medical device company specializing in PET and PET-CT (Positron Emission Tomography/Computed Tomography) imaging systems and clinical services, is pleased to announce sales of the Attrius PET and NeuSight PET-CT 64 slice nuclear imaging systems to a prominent  cardiology specialist in the assessment and treatment of cardiovascular disease and interventional cardiovascular services. These cutting-edge technologies are designed to provide unmatched diagnostic precision and value for nuclear cardiology and molecular imaging practices.

Life Molecular Imaging Secures FDA Fast Track Designation for [18F]Florbetaben in Diagnosing Cardiac AL and ATTR Amyloidosis

[18F]florbetaben has been granted a Fast Track designation for cardiac amyloidosis, which will expedite the development of [18F]florbetaben for this indication [18F]florbetaben previously received orphan drug status as a diagnostic for the management of AL amyloidosis in EU and US The…

NEXTBIOMEDICAL Receives IDE Approval from FDA for Nexsphere-F™, an Embolic Microsphere for Use in Genicular Artery Embolization (GAE) for Knee Osteoarthritis: The U.S. RESORB Trial Launches

SEOUL, South Korea, Jan. 15, 2025 /PRNewswire/ — NEXTBIOMEDICAL CO., LTD, a KOSDAQ-listed innovative medical device company in South Korea, proudly announced that it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) for its…